Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Walgreens Boots Alliance Inc (NASDAQ: WBA) ended roughly 5.0% down even though it reported better-than-expected results for its first financial quarter. Is Walgreens stock a ‘buy'?

Should you buy Walgreens stock on market-beating Q1 results?

Constellation Brands

Markets were lower, and even some upbeat comments from companies didn't lift their shares.

2 Falling Stocks Could Mean an Ugly Earnings Season Ahead

Amcor Plc

Franklin Resources

Essex Property Trust

Federal Realty Investment Trust

Leggett & Platt

Medtronic

Realty Income Corp

Stanley Black & Decker

Sysco

Target

T. Rowe Price Group

V.F.

"Dividend Aristocrats. in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years. "--Kiplinger.com/Investing. 65 Aristocrats screened as of January 3, 2022 represented all eleven Morningstar Sectors. Broker estimated-top-ten net-gains ranged 13.23%-26.61% topped by VFC & TGT.

5 Dividend Aristocrat Buys For January

The U.S. Healthcare segment of Walgreens Boots (WBA) grows on key contract wins, continued partnership growth and a strong focus on execution.

Walgreens Boots (WBA) Q1 Earnings Top, Revenues View Up

Walgreens-backed doctor clinic operator VillageMD now has a network over more than 680 locations across the U.S. including 200 adjacent to the pharmacy chain's U.S. drugstores.

Walgreens Has 200 VillageMD Clinics Attached To Stores As Doctor Network Takes Off

The quarterly results it delivered Thursday were fine, but the company faces headwinds.

Why Walgreens Boots Alliance Stock Is Falling Today

Walgreens Boots Alliance, Inc. (NASDAQ:WBA ) Q1 2023 Earnings Conference Call January 5, 2023 8:30 AM ET Company Participants Tiffany Kanaga - VP, Global IR Roz Brewer - CEO James Kehoe - CFO Rick Gates - SVP, Pharmacy and Healthcare at Walgreens Conference Call Participants A.J. Rice - Credit Suisse George Hill - Deutsche Bank Elizabeth Anderson - Evercore ISI Lisa Gill - JPMorgan Ann Hynes - Mizuho Securities Michael Cherny - Bank of America Operator Good morning.

Walgreens Boots Alliance, Inc. (WBA) Q1 2023 Earnings Call Transcript

Walgreens acknowledged it may have overblown concerns about thefts in their stores after shrinkage stabilized over the past year.

Walgreens executive says 'maybe we cried too much last year' about theft

The nation's second-largest chain of drug stores said Thursday (Jan. 5) it is moving forward with costly investments in technology.

Walgreens Says It Is ‘Reinventing the Pharmacy' With Micro-Fulfillment Centers

The net loss was driven by a $5.2 billion after-tax charge for opioid-related claims and litigation, the retail pharmacy chain said.

Walgreens Delivers a Mixed Bag: an Earnings Beat but a Net Loss

Walgreens Boots Alliance Inc (NASDAQ:WBA) is kicking off earnings for the Dow components, and bearish options traders have been quick to respond.

Put Traders Pounce on Walgreens Stock After Quarterly Report

Walgreens Boots Alliance Inc (NASDAQ:WBA) shares shed nearly 5% in pre-market deals in New York on Thursday as the drugstore chain giant swung to a loss in its first quarter as the company took a US$6.5 billion charge for opioid litigation. In the three months to end-November 2022, the company posted a loss per share of US$4.31, compared to earnings per share (EPS) of US$4.13 in the year-earlier quarter.

Walgreens Boots Alliance shares sink as drugstore giant reports first quarter loss on opioid litigation charge

Walgreens (WBA) delivered earnings and revenue surprises of 0.87% and 1.28%, respectively, for the quarter ended November 2022. Do the numbers hold clues to what lies ahead for the stock?

Walgreens Boots Alliance (WBA) Beats Q1 Earnings and Revenue Estimates

Cigna

CHICAGO & NEW YORK--( BUSINESS WIRE )--VillageMD announced today that on Jan. 3, 2023, it completed the previously disclosed acquisition of Summit Health-CityMD, a leading provider of primary, specialty and urgent care.

VillageMD Finalizes Acquisition of Summit Health-CityMD, Creating One of the Largest Independent Provider Groups in the U.S.

Amgen

Cisco Systems

Chevron

Dow Inc

Goldman Sachs

Intel

JPMorgan Chase & Co

Verizon

Owning the "Dogs Of The Dow" stocks paid off in 2022. And they could be even more lucrative this year.

'Dogs Of The Dow' Stocks Just Paid Off; Here Are The Top 10 For 2023

The drugstore chain swung to a quarterly loss due to previously disclosed $6.5 billion opioid settlement.

Walgreens Sales Fall as Demand for Covid Vaccines Wanes

Walgreens Beats Earnings Expectations but Posts Net Loss on Opioid Settlement

Drugstore chain Walgreens Boots Alliance Inc reported a net quarterly loss on Thursday as it took a $6.5 billion opioid litigation charge, sending its shares down nearly 2% in premarket trade.

Walgreens posts loss on $6.5 bln opioid litigation charge

Walgreens Boots Alliance [s: wba] had a loss of $3.7 billion, or $4.31 per share, in the first quarter of 2023. It had a profit of $3.6 billion, or $4.13, in the same quarter in 2022.

Walgreens beats revenue expectations in the first quarter

Walgreens reported a $3.7 billion loss in its fiscal first quarter thanks to its share of a massive global settlement with other drugstore chains to settle claims its pharmacies contributed to the opioid epidemic.

Opioid Settlement Drags Walgreens To $3.7 Billion Quarterly Loss

Walgreens Boots Alliance on Thursday reported fiscal first quarter earnings that beat Wall Street's estimates after an early flu season boosted demand for cough and cold medicine.

Walgreens tops estimates as early flu season helps drive sales

DEERFIELD, Ill.--( BUSINESS WIRE )--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced financial results for the first quarter of fiscal 2023, which ended November 30, 2022.

Walgreens Boots Alliance Reports Fiscal 2023 First Quarter Results

DEERFIELD, Ill.--( BUSINESS WIRE )--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that Chief Executive Officer, Roz Brewer, and Executive Vice President and Global Chief Financial Officer, James Kehoe, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, Jan. 10 at 11:15 a.m. PT (2:15 p.m. ET).

Walgreens Boots Alliance to Participate in 41st Annual J.P. Morgan Healthcare Conference

Disney

Johnson & Johnson

Visa

Among the Dow Jones Industrial Average's 30 components, there are five incredible deals just begging to be bought in the new year.

5 Dow Stocks That Make for No-Brainer Buys in 2023

Apple

Boeing

Salesforce

Microsoft

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation.is also a consideration.” – Dow Jones & Co. The highest-yield 10 are January's Dogs of the Dow: JPM, CVX, CSCO, AMGN, IBM, MMM, WBA, INTC, DOW and VZ are averaging a 4.51% annual yield.

News for Walgreens Stock (WBA)